Best Cholesterol Supplements On Cycle, Ranked by Evidence (2026)

Your lipid panel came back looking like a war zone. HDL in the teens, LDL climbing, triglycerides creeping up from the bulk. So you do what every bodybuilder does: you Google "best supplements for cholesterol on cycle" and get hit with a dozen affiliate-link listicles ranking products nobody has tested in anyone running 500 mg of test, let alone a stack with orals.

This article is different. We ranked every commonly recommended cholesterol supplement by what the clinical evidence actually shows: effect sizes from randomized controlled trials, not forum anecdotes. We separated them by what they actually target (LDL, HDL, or triglycerides) because steroid-induced dyslipidemia is not the same problem as your dad's high cholesterol. And we'll tell you when supplements are not enough and it's time to talk to a doctor about a statin.

If you haven't read our companion piece on how different compounds wreck your lipids, start there. This article picks up where that one left off: you know the problem, now here are the solutions.

How we ranked these supplements

Every supplement below is ranked into one of three tiers based on:

1. Quality of evidence: RCTs and meta-analyses beat case reports and animal studies
2. Effect size: a 5% LDL reduction is not the same as a 25% reduction
3. Relevance to steroid users: general-population cholesterol studies don't always translate to someone with an HDL of 18 mg/dL

One critical caveat: almost none of these supplements have been tested in people using anabolic steroids. We are extrapolating from studies in hyperlipidemic adults. The magnitude of benefit may be smaller when your lipids are disrupted by exogenous androgens and hepatic lipase upregulation rather than by diet and genetics alone.

Tier 1: Strong evidence

Omega-3 EPA/DHA

Primary target: Triglycerides

Omega-3 fatty acids are the most evidence-backed supplement for on-cycle lipid management, but not for the reason most people think. Fish oil is mediocre at lowering LDL and inconsistent at raising HDL. Where it excels is triglyceride reduction.

The American Heart Association recommends 4 g/day of EPA+DHA for hypertriglyceridemia, with expected reductions of 20-30% at moderate baseline levels and over 30% at severe levels (Skulas-Ray et al., 2019). The dose-response is nearly linear above 2 g/day with no plateau identified at supplemental doses.

There is an important distinction between EPA and DHA. The ComparED crossover trial (n=154) found that DHA raised LDL by approximately 3.3% compared to EPA, while EPA did not raise LDL at all (Allaire et al., 2018). The REDUCE-IT trial (n=8,179) tested 4 g/day pure EPA and showed a 25% relative reduction in cardiovascular events (Bhatt et al., 2019). If you're already dealing with elevated LDL on cycle, choose an EPA-dominant formulation.

Dose: 2-4 g of actual EPA+DHA per day (not total fish oil weight). A standard 1,000 mg fish oil capsule contains roughly 300 mg combined EPA+DHA. Reaching 3 g requires about 10 standard capsules daily, or a concentrated product.

Citrus bergamot

Primary target: LDL, total cholesterol

Bergamot is the most underrated cholesterol supplement in the bodybuilding space. It contains two unique flavonoids (brutieridin and melitidin) that inhibit HMG-CoA reductase, the same enzyme statins target, through competitive binding at the active site.

The numbers are impressive. Mollace et al. (2011) found that 500 mg/day of bergamot polyphenolic fraction reduced LDL by 24.1% and triglycerides by 30.5% in 237 hyperlipidemic patients over 30 days (Mollace et al., 2011). At 1,000 mg/day, LDL reductions reached 39-41%, comparable to rosuvastatin 10 mg.

That last point deserves emphasis. Gliozzi et al. (2014) directly compared bergamot to rosuvastatin in 77 patients. When combined, bergamot 1,000 mg/day + rosuvastatin 10 mg produced results equivalent to rosuvastatin 20 mg, demonstrating a meaningful statin-sparing effect (Gliozzi et al., 2014). This statin-sparing effect matters for athletes who want lipid control without doubling their statin dose.

Beyond the basic lipid panel, Toth et al. (2016) found six months of bergamot reduced small dense LDL particles (the most atherogenic subtype) by 38-67% and decreased carotid intima-media thickness by 25%, suggesting actual vascular benefit (Toth et al., 2016).

Dose: 500 mg twice daily of a standardized extract (25-35% polyphenolic content). Unstandardized bergamot juice or extracts have variable polyphenol content and unpredictable efficacy.

Red yeast rice: proceed with caution

Primary target: LDL

Red yeast rice (RYR) consistently delivers impressive LDL reductions. A 2022 meta-analysis of 15 RCTs found an average LDL reduction of 35.8 mg/dL, with no significant difference from pharmaceutical statins (Li et al., 2022).

Here is the catch: the active compound in red yeast rice, monacolin K, is chemically identical to lovastatin. Not similar. Identical. This is literally a statin sold as a supplement, which means it carries all the same risks: myopathy, rhabdomyolysis, hepatotoxicity, and CYP3A4 drug interactions.

It gets worse. Commercial RYR products contain anywhere from 0.09 mg to 10.94 mg of monacolin K per dose, making consistent dosing impossible without third-party testing. The EFSA documented severe musculoskeletal adverse events, including rhabdomyolysis, at doses as low as 3 mg/day monacolin K. Multiple independent analyses have found citrinin, a nephrotoxic mycotoxin, in commercial RYR supplements (EFSA, 2018).

For steroid users specifically, the hepatotoxicity risk compounds directly with the liver stress from 17-alpha-alkylated oral AAS like Winstrol or Anadrol. If your cholesterol requires statin-level intervention, get a prescription statin with a known dose, verified purity, and proper monitoring. Don't gamble on an unregulated supplement that is pharmacologically identical but quality-controlled like a mystery box.

Tier 2: Moderate evidence

Berberine

Primary target: LDL, triglycerides, fasting glucose

Berberine is the Swiss Army knife of this list. It lowers LDL by about 15-18 mg/dL, triglycerides by 18-30 mg/dL, and has a clinically meaningful glucose-lowering effect that makes it uniquely useful for athletes running MK-677.

The largest meta-analysis to date (41 RCTs, 4,838 patients) found a mean LDL reduction of 14.98 mg/dL (Hernandez et al., 2024). A placebo-controlled analysis (18 RCTs, 1,788 patients) confirmed approximately 18 mg/dL LDL reduction (Blais et al., 2023).

The mechanism is interesting: berberine activates AMPK, which suppresses PCSK9 (the protein that degrades LDL receptors on liver cells). Lab studies showed berberine decreased PCSK9 mRNA by 77% and protein by 87% in hepatocytes (Ataei et al., 2022). The result is more LDL receptors on liver cells and faster LDL clearance from your blood.

The glucose angle matters. Yin et al. (2008) found berberine 500 mg three times daily reduced HbA1c from 9.5% to 7.5% and fasting glucose from 10.6 to 6.9 mmol/L, comparable to metformin (Yin et al., 2008). If you're running MK-677 and watching your fasting glucose climb (as covered in our MK-677 insulin resistance guide), berberine addresses both lipids and glucose in one supplement.

Dose: 500 mg two to three times daily with meals. Start at 500 mg once daily and titrate up to reduce GI side effects (nausea, diarrhea).

Plant sterols and stanols

Primary target: LDL

Plant sterols are structurally similar to cholesterol and compete with it for absorption in the gut. The evidence is solid but modest: a definitive meta-analysis of 124 RCTs (9,600 participants) found 6-12% LDL reduction across 0.6-3.3 g/day, plateauing at about 3 g/day (Ras et al., 2014). At the standard 2 g/day dose, expect roughly 8-10% LDL reduction.

The FDA authorized a health claim for plant sterols at 2 g/day. That said, they have no effect on HDL (your primary problem on cycle) and no hard cardiovascular outcome data exists. They are an additive tool, not a standalone solution.

Plant sterols stack safely with statins. A meta-analysis found an additional 12 mg/dL LDL reduction when added to statin therapy.

Dose: 2-3 g/day, taken with meals.

Niacin: the complicated one

Primary target: HDL (in theory)

Niacin is the only supplement on this list that meaningfully raises HDL: 15-35% increases with immediate-release nicotinic acid at 1,000-2,000 mg/day. For athletes watching their HDL crash into single digits on Winstrol or tren, that sounds like exactly what you need.

There is a problem. A big one.

The AIM-HIGH trial (3,414 patients, 36 months) tested niacin on top of statin therapy. Niacin raised HDL from 35 to 42 mg/dL (+20%) and lowered LDL and triglycerides as expected. But the primary cardiovascular endpoint was identical between groups: 16.4% niacin vs 16.2% placebo. The trial was stopped early for futility (Boden et al., 2011). The larger HPS2-THRIVE trial (25,673 patients) confirmed: niacin improved lipid numbers but did not reduce cardiovascular events. A Cochrane meta-analysis of 23 RCTs (39,195 participants) concluded that "benefits from niacin therapy in the prevention of cardiovascular disease events are unlikely" (Schandelmaier et al., 2017).

The takeaway: pharmacologically raising the HDL number on your lab report is not the same as restoring functional HDL that actually protects your arteries. This distinction matters for steroid users, whose HDL is suppressed through hepatic lipase upregulation, not simple depletion.

Two more problems. First, "flush-free" niacin (inositol hexanicotinate) does not work. Keenan et al. (2013) showed it was no better than placebo for any lipid parameter because it is not absorbed as free nicotinic acid (Keenan, 2013). If your niacin bottle says "no flush," put it back on the shelf. Second, niacin worsens glucose tolerance, compounding the metabolic burden if you're already dealing with MK-677 or GH-related insulin resistance.

Our position: we do not recommend niacin as a standard part of on-cycle lipid management. The HDL number improvement does not translate to cardiovascular protection, the flush and adherence burden are high, and it worsens glucose control. If you insist on trying it, use only immediate-release nicotinic acid (not flush-free, not sustained-release), and monitor fasting glucose and liver enzymes closely.

Tier 3: Weak or emerging evidence

These supplements have some data behind them but either the effect sizes are small, the evidence is inconsistent, or both.

Psyllium and soluble fibre

The most evidence-backed option in this tier. A meta-analysis of 28 RCTs found approximately 13 mg/dL LDL reduction at 10 g/day (Jovanovski et al., 2018). The mechanism is straightforward: psyllium's viscous gel binds bile acids in the gut, forcing your liver to pull more cholesterol from blood to synthesize replacements. It also reduces ApoB by about 0.05 g/L. No effect on HDL or triglycerides. Cheap, safe, and stacks with everything. 10 g/day in water with meals.

CoQ10

CoQ10 does not directly lower cholesterol. Its role is as a statin adjunct. Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and CoQ10 synthesis in the mevalonate pathway, depleting circulating CoQ10 levels. The clinical evidence for reducing statin-associated muscle symptoms is inconsistent: a meta-analysis of 8 RCTs found no significant benefit for CK levels or muscle pain (Wei et al., 2022). Still, the rationale strengthens for steroid users because oral AAS independently stress mitochondrial function through oxidative pathways. If you start a statin on cycle, 200 mg/day ubiquinol is low-risk insurance.

Aged garlic extract

A meta-analysis found a modest LDL reduction of about 4 mg/dL (Ried, 2016). A 2022 RCT at 1.25 mg SAC daily for 6 weeks found no significant difference from placebo (Valls et al., 2022). The evidence is too inconsistent to recommend for on-cycle lipid management.

Probiotics

Genuinely emerging territory. Certain strains with bile salt hydrolase activity can deconjugate bile acids, mimicking the psyllium mechanism enzymatically. The best-studied strain, Lactobacillus reuteri NCIMB 30242, reduced LDL by 11.6% in a 9-week RCT (Jones et al., 2012). A broader meta-analysis of 30 RCTs found 7.3 mg/dL LDL reduction, but effects varied substantially by strain (Cho & Kim, 2015). Interesting, but too early and too strain-specific to recommend broadly.

The comparison table

Matching your stack to your supplement protocol

Not all cycles wreck your lipids equally. Here's how to calibrate your supplement approach based on what you're running. (For the full compound-by-compound impact breakdown, see our cholesterol on steroids guide.)

Running oral AAS

If your cycle includes Winstrol, Superdrol, Halotestin, Anadrol, or Dianabol, your HDL will likely drop below 20 mg/dL and LDL will climb. These 17-alpha-alkylated compounds upregulate hepatic triglyceride lipase aggressively, and no supplement can fully counteract that mechanism.

Recommended protocol: Omega-3 (3-4 g EPA+DHA/day) + citrus bergamot (500 mg 2x/day) + berberine (500 mg 2-3x/day if glucose is also elevated). Add psyllium (10 g/day) for additional LDL lowering. Time-limit the oral to 4-6 weeks. Check your lipid panel at mid-cycle and end of cycle. If LDL exceeds 4.5 mmol/L (174 mg/dL) or ApoB exceeds 1.2 g/L, it's time for the statin conversation.

Injectable-only cycles

Testosterone at moderate doses (300-500 mg/week) typically drops HDL by 20-30%, not 60-80%. Adding nandrolone or EQ adds some additional pressure. Trenbolone is the exception: despite being injectable, it suppresses HDL aggressively and case reports show single-digit HDL values.

Recommended protocol: Omega-3 (2-3 g EPA+DHA/day) + citrus bergamot (500 mg 2x/day). This is where the supplement stack has the most realistic chance of producing measurable benefit, because the magnitude of disruption is lower. For tren-inclusive stacks, treat it like an oral-containing cycle.

TRT dose with AI

Here is a scenario many TRT patients overlook. Aggressive anastrozole or letrozole use removes estrogen's natural brake on hepatic lipase, compounding the lipid damage from testosterone itself. This is covered in detail in our estradiol guide. Before stacking cholesterol supplements, consider whether your AI dose is too aggressive. Reducing AI use may do more for your lipids than any supplement.

Recommended protocol: Omega-3 (2 g EPA+DHA/day) + citrus bergamot (500 mg 2x/day). Reassess AI dosing. Test estradiol alongside your lipid panel.

When supplements are not enough: the statin question

The SPORT trial (2023) tested fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice head-to-head against rosuvastatin 5 mg (a quarter of the max dose). None of the supplements produced a statistically significant LDL reduction compared to placebo. Rosuvastatin 5 mg reduced LDL by 35.2% (Laffin et al., 2023).

That does not mean supplements are useless. But it means that for severe dyslipidemia, a low-dose statin will outperform your entire supplement stack combined.

Talk to your doctor about a statin if:

• LDL stays above 4.5 mmol/L (174 mg/dL) on cycle despite supplements
• ApoB exceeds 1.2 g/L
• HDL is below 0.7 mmol/L (27 mg/dL) with concurrent LDL elevation
• You're running cycles longer than 12 weeks with multiple cardiovascular risk factors

If you go the statin route, rosuvastatin is generally preferred over atorvastatin for steroid users. Rosuvastatin is minimally metabolized by CYP3A4 (avoiding interactions with oral AAS that share this pathway) and has a lower hepatotoxicity signal in pharmacovigilance data. Add CoQ10 200 mg/day as mitochondrial insurance.

One hard rule: do not combine a statin with hepatotoxic oral AAS without monthly ALT/AST monitoring. The additive liver stress is real. If your liver enzymes exceed 2x ULN, discontinue the statin or the oral, preferably the oral. For more on interpreting your liver values, see our liver enzymes on steroids guide.

How long to continue post-cycle

Lipid recovery is not instant, and stopping supplements the day you drop the compounds is a mistake.

Injectable-only cycles: continue the full supplement protocol for 4-6 weeks post-cycle. Hartgens et al. (2004) found that after 8 weeks of AAS use, HDL and ApoB had still not returned to baseline at 6 weeks post-cessation (Hartgens et al., 2004). Test your lipids at week 4 and week 8 off. If both panels show recovery, you can taper.

Oral-heavy cycles: extend supplements for 8-12 weeks minimum. The HTGL upregulation from 17-alpha-alkylated compounds causes deeper HDL suppression through a different pathway than injectables, and recovery is correspondingly slower. Expect 12-20 weeks for HDL to normalize.

Targets before stopping supplements:

• LDL below 3.0 mmol/L (116 mg/dL)
• HDL above 1.0 mmol/L (39 mg/dL)
• Non-HDL below 3.8 mmol/L
• ApoB below 1.0 g/L
• Triglycerides below 2.0 mmol/L

Confirm these on two consecutive tests 4-6 weeks apart before fully stopping. For the full lipid recovery timeline and PCT bloodwork targets, check our dedicated guides.

If you have any pre-existing cardiovascular risk factors (family history, hypertension, elevated Lp(a)), consider maintaining omega-3 and bergamot indefinitely between cycles.

Takeaways

• Omega-3 EPA/DHA is your foundation: strongest evidence for triglyceride reduction, mild HDL benefit, prefer EPA-dominant formulations to avoid LDL elevation from DHA
• Citrus bergamot is the most underrated option: 24-41% LDL reduction at 500-1,000 mg/day, comparable to low-dose rosuvastatin, plus small dense LDL particle reduction
• Red yeast rice is literally lovastatin sold as a supplement: effective but carries statin-level risks with supplement-level quality control. Get a real statin instead.
• Berberine is the best choice for dual lipid + glucose management, especially on MK-677: 15-18 mg/dL LDL reduction plus meaningful glucose lowering
• Niacin raises the HDL number but AIM-HIGH proved this does not reduce cardiovascular events. Flush-free niacin does not work at all. Not recommended as standard protocol.
• Plant sterols are a safe LDL add-on (8-10% reduction) but do nothing for HDL
• No supplement matches even a low-dose statin. If LDL exceeds 4.5 mmol/L or ApoB exceeds 1.2 g/L on cycle, talk to your doctor.
• Continue supplements 4-12 weeks post-cycle depending on oral vs injectable, and confirm recovery on two consecutive blood tests before stopping

---

References

1. Skulas-Ray, A. C., et al. (2019). Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the American Heart Association. Circulation, 140(12), e673-e691. PubMed

2. Bhatt, D. L., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 380(1), 11-22. PubMed

3. Allaire, J., et al. (2018). A randomized, crossover, head-to-head comparison of EPA and DHA supplementation (ComparED). Journal of Clinical Endocrinology and Metabolism, 103(8), 2909-2917. PubMed

4. Mollace, V., et al. (2011). Hypolipemic and hypoglycaemic activity of bergamot polyphenols. Fitoterapia, 82(3), 309-316. PubMed

5. Gliozzi, M., et al. (2014). Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol. International Journal of Cardiology, 170(2), 140-145. PubMed

6. Toth, P. P., et al. (2016). Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis. Frontiers in Pharmacology, 6, 299. PubMed

7. Li, Z., et al. (2022). Red yeast rice for hyperlipidemia: A meta-analysis of 15 high-quality RCTs. Frontiers in Pharmacology, 12, 819482. PubMed

8. EFSA NDA Panel. (2018). Scientific opinion on the safety of monacolins in red yeast rice. EFSA Journal, 16(8), e05368. PMC

9. Hernandez, A. V., et al. (2024). Impact of berberine on lipoprotein, triglyceride and biological safety marker concentrations. Journal of Dietary Supplements, 21(2). PubMed

10. Blais, J. E., et al. (2023). Overall and sex-specific effect of berberine for dyslipidemia: A systematic review and meta-analysis. Drugs, 83(5), 403-425. PubMed

11. Ataei, S., et al. (2022). Berberine: Ins and outs of a nature-made PCSK9 inhibitor. EXCLI Journal, 21, 1263-1279. PMC

12. Yin, J., et al. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712-717. PubMed

13. Ras, R. T., et al. (2014). LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges. British Journal of Nutrition, 112(2), 214-219. PubMed

14. Boden, W. E., et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (AIM-HIGH). New England Journal of Medicine, 365(24), 2255-2267. PubMed

15. Schandelmaier, S., et al. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database of Systematic Reviews, 6, CD009744. PubMed

16. Keenan, J. M. (2013). Wax-matrix extended-release niacin vs inositol hexanicotinate. Journal of Clinical Lipidology, 7(1), 14-23. PubMed

17. Jovanovski, E., et al. (2018). Effect of psyllium fiber on LDL cholesterol and alternative lipid targets. American Journal of Clinical Nutrition, 108(5), 922-932. PubMed

18. Wei, H., et al. (2022). Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis. Irish Journal of Medical Science, 191(2), 719-725. PubMed

19. Jones, M. L., et al. (2012). Cholesterol lowering by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European Journal of Clinical Nutrition, 66(11), 1234-1241. PubMed

20. Cho, Y. A., & Kim, J. (2015). Effect of probiotics on blood lipid concentrations: a meta-analysis. Medicine, 94(43), e1714. PubMed

21. Laffin, L. J., et al. (2023). Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids (SPORT trial). Journal of the American College of Cardiology, 81(1), 1-12. PubMed

22. Hartgens, F., et al. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). British Journal of Sports Medicine, 38(3), 253-259. PubMed

23. Urhausen, A., et al. (2003). Reversibility of the effects on blood cells, lipids, liver function and hormones in former AAS abusers. Journal of Steroid Biochemistry and Molecular Biology, 84(2-3), 369-375. PubMed